Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya.

Journal: Diabetes, obesity & metabolism
PMID: 38618987

Abstract

AIM: Hypertension and diabetes mellitus (DM) are major causes of morbidity and mortality, with growing burdens in low-income countries where they are underdiagnosed and undertreated. Advances in machine learning may provide opportunities to enhance diagnostics in settings with limited medical infrastructure.

Authors

  • Tom White
    Data Science and Advanced Analytics, Data Science & Artificial Intelligence, R&D, AstraZeneca, Cambridge, UK.
  • Viknesh Selvarajah
    Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Fredrik Wolfhagen-Sand
    Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Nils Svangård
    Data Science and Advanced Analytics, Data Science & Artificial Intelligence, R&D, AstraZeneca, Gothenburg, Sweden.
  • Gayathri Mohankumar
    Centre for Artificial Intelligence, Data Science & Artificial Intelligence, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Peter Fenici
    School of Medicine and Surgery, Catholic University, Rome, Italy.
  • Kathryn Rough
    1Google LLC, Mountain View, CA USA.
  • Nelson Onyango
    IQVIA, Durham, North Carolina, USA.
  • Kendall Lyons
    IQVIA, Durham, North Carolina, USA.
  • Christina Mack
    IQVIA, Durham, North Carolina, USA.
  • Videlis Nduba
    Kenya Medical Research Institute, Nairobi, Kenya.
  • Mansoor Noorali Saleh
    Clinical Research Unit, Aga Khan University Hospital, Nairobi, Kenya.
  • Innocent Abayo
    Clinical Research Unit, Aga Khan University Hospital, Nairobi, Kenya.
  • Afrah Siddiqui
    BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Malgorzata Majdanska-Strzalka
    CVRM Clinical Operations, Biopharmaceuticals, R&D, AstraZeneca, Warsaw, Poland.
  • Katarzyna Kaszubska
    CVRM Clinical Operations, Biopharmaceuticals, R&D, AstraZeneca, Warsaw, Poland.
  • Tove Hegelund-Myrback
    Global Portfolio & Project Management, Early CVRM&NS, R&D, AstraZeneca, Gothenburg, Sweden.
  • Russell Esterline
    Research and Late Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
  • Antonio Manzur
    Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Victoria E R Parker
    Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Keywords

External Resources

Popular Topics
Recent Journals